Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

被引:6
作者
Mooradian, Meghan J. [1 ,2 ,5 ]
Cai, Ling [3 ]
Wang, Alice [3 ]
Qiao, Yao [3 ]
Chander, Pratibha [3 ]
Whitaker, Ryan M. [4 ]
机构
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Harvard Med Sch, 55 Fruit St, Boston, MA 02114 USA
[3] AstraZeneca, Gaithersburg, MD USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Massachusetts Gen Hosp, Div Hematol Oncol, Med, Canc Ctr, 55 Fruit St, Boston, MA 02114 USA
关键词
RANDOMIZED PHASE-III; CONSOLIDATION CHEMOTHERAPY; CONCURRENT; CISPLATIN; RADIOTHERAPY; DOCETAXEL; TRIAL; RADIATION; ETOPOSIDE; ONCOLOGY;
D O I
10.1001/jamanetworkopen.2024.7542
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance The PACIFIC trial established consolidation durvalumab as the standard of care following chemoradiotherapy (CRT) for patients with unresectable stage III non-small cell lung cancer (NSCLC). Understanding its benefit in routine US clinical practice is critical. Objective To report characteristics, treatment patterns, and outcomes of patients who did or did not receive durvalumab. Design, Setting, and Participants Two prespecified cohorts were curated in this retrospective cohort study (SPOTLIGHT). Deidentified patient-level data from a US database (Flatiron Health) were analyzed. Patients had unresectable stage III NSCLC, were diagnosed on or after January 1, 2011, had 2 or more visits on or afterward, and received CRT. Data were analyzed from May 2021 to October 2023. Exposures Patients started durvalumab after CRT (durvalumab cohort) or ended CRT without durvalumab (nondurvalumab cohort) by June 30, 2019, to allow 15 or more months of follow-up from CRT end. Main Outcomes and Measures End points included progression-free survival (PFS), overall survival (OS), time to first subsequent therapy or death (TFST), and time to distant metastasis or death (TTDM). Results The durvalumab cohort included 332 patients (median [IQR] age, 67.5 [60.8-74.0] years; 187 were male [56.3%], 27 were Black [8.7%], 33 were other races [10.7%], and 249 were White [80.6%]) and the nondurvalumab cohort included 137 patients (median (IQR) age, 70.0 [64.0-75.0] years; 89 [65.0%] were male, 11 [8.9%] were Black, 19 [15.4%] were other races, and 93 [75.6%] were White). Most patients had a smoking history (durvalumab, 316 patients [95.2%] and nondurvalumab, 132 patients [96.4%]) and Eastern Cooperative Oncology Group performance status 0 through 1 (durvalumab, 251 patients [90.9%] and nondurvalumab, 88 patients [81.5%]). Median (IQR) CRT duration was 1.6 (1.4-1.8) months for the durvalumab cohort and 1.5 (1.4-1.8) months for the nondurvalumab cohort. Median time to durvalumab discontinuation was 9.5 months (95% CI, 7.8-10.6 months). Median TFST and TTDM were not reached (NR) in the durvalumab cohort and 8.3 months (95% CI, 4.8-11.8 months) and 11.3 months (95% CI, 6.4-14.5 months), respectively, in the nondurvalumab cohort. Median PFS and OS were 17.5 months (95% CI, 13.6-24.8 months) and NR in the durvalumab cohort and 7.6 months (95% CI, 5.2-9.8 months) and 19.4 months (95% CI, 11.7-24.0 months) in the nondurvalumab cohort. In Cox regression analyses of patients who completed concurrent CRT without progression, durvalumab was associated with a lower risk of progression or death (hazard ratio [HR], 0.36; 95% CI, 0.26-0.51) and lower risk of death (HR, 0.27; 95% CI, 0.16-0.43), adjusted for prior platinum agent and patient characteristics. Conclusions and Relevance In this cohort study, findings were consistent with PACIFIC, and durvalumab was associated with a lower risk of progression and/or death. Further investigation is warranted to explain why patients did not receive durvalumab after its approval.
引用
收藏
页数:11
相关论文
共 21 条
[1]   Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 [J].
Ahn, Jin Seok ;
Ahn, Yong Chan ;
Kim, Joo-Hang ;
Lee, Chang Geol ;
Cho, Eun Kyung ;
Lee, Kyu Chan ;
Chen, Ming ;
Kim, Dong-Wan ;
Kim, Hoon-Kyo ;
Min, Young Joo ;
Kang, Jin-Hyoung ;
Choi, Jin-Hyuck ;
Kim, Sang-We ;
Zhu, Guangying ;
Wu, Yi-Long ;
Kim, Sung Rok ;
Lee, Kyung Hee ;
Song, Hong Suk ;
Choi, Yoon-La ;
Sun, Jong-Mu ;
Jung, Sin-Ho ;
Ahn, Myung-Ju ;
Park, Keunchil .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) :2660-U124
[2]   Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Kurata, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
Carpeno, J. de Castro ;
Faivre-Finn, C. ;
Reck, M. ;
Vansteenkiste, J. ;
Spigel, D. R. ;
Wadsworth, C. ;
Melillo, G. ;
Taboada, M. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350
[3]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[4]   Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy [J].
Aredo, Jacqueline V. ;
Mambetsariev, Isa ;
Hellyer, Jessica A. ;
Amini, Arya ;
Neal, Joel W. ;
Padda, Sukhmani K. ;
McCoach, Caroline E. ;
Riess, Jonathan W. ;
Cabebe, Elwyn C. ;
Naidoo, Jarushka ;
Abuali, Tariq ;
Salgia, Ravi ;
Loo Jr, Billy W. ;
Diehn, Maximilian ;
Han, Summer S. ;
Wakelee, Heather A. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) :1030-1041
[5]   Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].
Auperin, Anne ;
Le Pechoux, Cecile ;
Rolland, Estelle ;
Curran, Walter J. ;
Furuse, Kiyoyuki ;
Fournel, Pierre ;
Belderbos, Jose ;
Clamon, Gerald ;
Ulutin, Hakki Cuneyt ;
Paulus, Rebecca ;
Yamanaka, Takeharu ;
Bozonnat, Marie-Cecile ;
Uitterhoeve, Apollonia ;
Wang, Xiaofei ;
Stewart, Lesley ;
Arriagada, Rodrigo ;
Burdett, Sarah ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190
[6]   Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].
Bradley, Jeffrey D. ;
Paulus, Rebecca ;
Komaki, Ritsuko ;
Masters, Gregory ;
Blumenschein, George ;
Schild, Steven ;
Bogart, Jeffrey ;
Hu, Chen ;
Forster, Kenneth ;
Magliocco, Anthony ;
Kavadi, Vivek ;
Garces, Yolanda I. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Cliff ;
Wynn, Raymond B. ;
Koprowski, Christopher ;
Meng, Joanne ;
Beitler, Jonathan ;
Gaur, Rakesh ;
Curran, Walter, Jr. ;
Choy, Hak .
LANCET ONCOLOGY, 2015, 16 (02) :187-199
[7]  
Flentje M, 2016, STRAHLENTHER ONKOL, V192, P216, DOI 10.1007/s00066-016-0941-8
[8]   Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study [J].
Girard, Nicolas ;
Bar, Jair ;
Garrido, Pilar ;
Garassino, Marina C. ;
McDonald, Fiona ;
Mornex, Francoise ;
Filippi, Andrea R. ;
Smit, Hans J. M. ;
Peters, Solange ;
Field, John K. ;
Christoph, Daniel C. ;
Sibille, Anne ;
Fietkau, Rainer ;
Haakensen, Vilde D. ;
Chouaid, Christos ;
Markman, Ben ;
Hiltermann, T. Jeroen N. ;
Taus, Alvaro ;
Sawyer, William ;
Allen, Allison ;
Chander, Pratibha ;
Licour, Muriel ;
Solomon, Benjamin .
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) :181-193
[9]   Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer: The Hoosier Oncology Group and US Oncology [J].
Hanna, Nasser ;
Neubauer, Marcus ;
Yiannoutsos, Constantin ;
McGarry, Ronald ;
Arseneau, James ;
Ansari, Rafat ;
Reynolds, Craig ;
Govindan, Ramaswamy ;
Melnyk, Anton ;
Fisher, William ;
Richards, Donald ;
Bruetman, Daniel ;
Anderson, Thomas ;
Chowhan, Naveed ;
Nattam, Sreenivasa ;
Mantravadi, Prasad ;
Johnson, Cynthia ;
Breen, Tim ;
White, Angela ;
Einhorn, Lawrence .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5755-5760
[10]   Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis [J].
Hansen, Ryan N. ;
Zhang, Yiduo ;
Seal, Brian ;
Ryan, Kellie ;
Yong, Candice ;
Darilay, Annie ;
Ramsey, Scott D. .
BMC CANCER, 2020, 20 (01)